Actinium gets NYSE plan acceptance through Nov 2027; adds Actimab-A patents and manufacturing

Actinium Pharmaceuticals, Inc.

NYSE Regulation accepted compliance plan; listing extended through Nov 27, 2027, maximum period under Section 1009.
Three US patents issued for Actimab-A: US 12,491,274 (sarcoma), US 12,539,340 (solid tumors), US 12,410,249 (low blast AML).
Canadian applications for venetoclax combo and CLAG-M combo advanced to pre-grant/allowed status.
Added second manufacturer under IND; will supply NCI CRADA and company studies with milestones from H2 2026.
Company remains non-compliant with Sections 1003(a)(ii) and (iii); delisting risk if plan not met by Nov 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.